Sichuan Biokin Pharmaceutical (688506.SH): T-Bren (HER2 ADC) completed the first subject enrollment in the Phase III clinical trial for locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Sichuan Biokin Pharmaceutical (688506.SH) announced that the company's independently developed innovative biopharmaceutical injection T-Bren (HER2 ADC) has completed the enrollment of the first subject in a Phase III clinical trial for HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that has failed first-line anti-HER2 therapy. T-Bren (BL-M07D1) is a novel ADC targeting HER2 with the potential to be best-in-class, and has demonstrated significant anti-tumor efficacy in clinical trials. Recently, the clinical study of T-Bren in HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma that has failed first-line anti-HER2 therapy has entered Phase III clinical trial stage and completed enrollment of the first subject. To date, T-Bren is conducting 13 clinical trials domestically and internationally, including 4 Phase III, 1 Phase II/III, 2 Phase II, 3 Phase I/II, and 3 Phase I clinical trials, covering indications such as first-line and second-line HER2-positive breast cancer, HER2-positive breast cancer adjuvant therapy post-surgery, HER2-positive breast cancer neoadjuvant therapy, low HER2-expressing breast cancer, HER2-positive gastric or gastroesophageal junction adenocarcinoma, as well as lung cancer, gastrointestinal tumors, urological tumors, and gynecological tumors.